12/7
05:11 am
capr
Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached [Seeking Alpha]
Low
Report
Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached [Seeking Alpha]
12/2
04:29 pm
capr
Capricor Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]
High
Report
Capricor Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]
12/2
04:15 pm
capr
Capricor Therapeutics to Present at Upcoming Investor Conferences
High
Report
Capricor Therapeutics to Present at Upcoming Investor Conferences
11/20
10:48 am
capr
Capricor wins key EU designations for the lead asset [Seeking Alpha]
Low
Report
Capricor wins key EU designations for the lead asset [Seeking Alpha]
11/20
10:22 am
capr
Parent Project Muscular Dystrophy Culminates 30th Anniversary with Celebratory "Investing in Every Future" Event [Yahoo! Finance]
Low
Report
Parent Project Muscular Dystrophy Culminates 30th Anniversary with Celebratory "Investing in Every Future" Event [Yahoo! Finance]
11/20
09:08 am
capr
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency [Yahoo! Finance]
Low
Report
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency [Yahoo! Finance]
11/20
09:00 am
capr
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
Low
Report
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
11/15
06:32 am
capr
Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
Low
Report
Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
11/14
01:34 pm
capr
Capricor Therapeutics Inc (NASDAQ: CAPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $77.00 price target on the stock.
Medium
Report
Capricor Therapeutics Inc (NASDAQ: CAPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $77.00 price target on the stock.
11/14
09:06 am
capr
Capricor Therapeutics Inc (NASDAQ: CAPR) had its price target raised by analysts at Cantor Fitzgerald from $25.00 to $30.00. They now have an "overweight" rating on the stock.
Medium
Report
Capricor Therapeutics Inc (NASDAQ: CAPR) had its price target raised by analysts at Cantor Fitzgerald from $25.00 to $30.00. They now have an "overweight" rating on the stock.
11/13
04:01 pm
capr
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/12
09:00 am
capr
Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting
Medium
Report
Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting
11/7
11:31 am
capr
Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
Low
Report
Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
11/5
09:00 am
capr
Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13
Low
Report
Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13
11/4
05:38 pm
capr
Exosome Therapies on the Rise as 70+ Major Companies Driving Development in the Field | DelveInsight [Yahoo! Finance]
Low
Report
Exosome Therapies on the Rise as 70+ Major Companies Driving Development in the Field | DelveInsight [Yahoo! Finance]
10/25
10:47 am
capr
Here's What Could Help Capricor (CAPR) Maintain Its Recent Price Strength [Yahoo! Finance]
Low
Report
Here's What Could Help Capricor (CAPR) Maintain Its Recent Price Strength [Yahoo! Finance]
10/22
05:21 pm
capr
Capricor Therapeutics files to sell 2.8M shares of common stock for holders [Seeking Alpha]
Medium
Report
Capricor Therapeutics files to sell 2.8M shares of common stock for holders [Seeking Alpha]
10/21
08:31 am
capr
Capricor Therapeutics Inc (NASDAQ: CAPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $35.00 price target on the stock.
Medium
Report
Capricor Therapeutics Inc (NASDAQ: CAPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $35.00 price target on the stock.
10/18
04:01 pm
capr
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Medium
Report
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
10/17
06:13 am
capr
Capricor Therapeutics stock falls after pricing $75M equity offering [Seeking Alpha]
Low
Report
Capricor Therapeutics stock falls after pricing $75M equity offering [Seeking Alpha]
10/17
06:00 am
capr
Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock
Low
Report
Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock
10/16
04:24 pm
capr
Capricor Therapeutics proposes public offering of common stock [Seeking Alpha]
Low
Report
Capricor Therapeutics proposes public offering of common stock [Seeking Alpha]
10/16
04:17 pm
capr
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
Medium
Report
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
10/14
08:23 am
capr
Capricor touts long-term efficacy of DMD therapy ahead of FDA application [Yahoo! Finance]
High
Report
Capricor touts long-term efficacy of DMD therapy ahead of FDA application [Yahoo! Finance]
10/11
09:15 am
capr
Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress
Medium
Report
Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress